JP2015534564A - 脱髄障害の治療のための併用療法および使用 - Google Patents

脱髄障害の治療のための併用療法および使用 Download PDF

Info

Publication number
JP2015534564A
JP2015534564A JP2015535889A JP2015535889A JP2015534564A JP 2015534564 A JP2015534564 A JP 2015534564A JP 2015535889 A JP2015535889 A JP 2015535889A JP 2015535889 A JP2015535889 A JP 2015535889A JP 2015534564 A JP2015534564 A JP 2015534564A
Authority
JP
Japan
Prior art keywords
lingo
seq
antibody molecule
antibody
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015535889A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015534564A5 (fr
Inventor
ディエゴ カデイビッド，
ディエゴ カデイビッド，
シャ ミ，
シャ ミ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of JP2015534564A publication Critical patent/JP2015534564A/ja
Publication of JP2015534564A5 publication Critical patent/JP2015534564A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
    • A61B5/112—Gait analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
    • A61B5/1124—Determining motor skills
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dentistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
JP2015535889A 2012-10-09 2013-10-08 脱髄障害の治療のための併用療法および使用 Withdrawn JP2015534564A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261711638P 2012-10-09 2012-10-09
US61/711,638 2012-10-09
PCT/US2013/063873 WO2014058875A2 (fr) 2012-10-09 2013-10-08 Polythérapies et leurs utilisations pour le traitement de troubles de la démyélinisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017247590A Division JP2018044014A (ja) 2012-10-09 2017-12-25 脱髄障害の治療のための併用療法および使用

Publications (2)

Publication Number Publication Date
JP2015534564A true JP2015534564A (ja) 2015-12-03
JP2015534564A5 JP2015534564A5 (fr) 2016-11-24

Family

ID=49484444

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015535889A Withdrawn JP2015534564A (ja) 2012-10-09 2013-10-08 脱髄障害の治療のための併用療法および使用
JP2017247590A Withdrawn JP2018044014A (ja) 2012-10-09 2017-12-25 脱髄障害の治療のための併用療法および使用
JP2020004952A Withdrawn JP2020055881A (ja) 2012-10-09 2020-01-16 脱髄障害の治療のための併用療法および使用
JP2021176294A Pending JP2022023182A (ja) 2012-10-09 2021-10-28 脱髄障害の治療のための併用療法および使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017247590A Withdrawn JP2018044014A (ja) 2012-10-09 2017-12-25 脱髄障害の治療のための併用療法および使用
JP2020004952A Withdrawn JP2020055881A (ja) 2012-10-09 2020-01-16 脱髄障害の治療のための併用療法および使用
JP2021176294A Pending JP2022023182A (ja) 2012-10-09 2021-10-28 脱髄障害の治療のための併用療法および使用

Country Status (13)

Country Link
US (4) US20150238602A1 (fr)
EP (2) EP3750560A3 (fr)
JP (4) JP2015534564A (fr)
KR (2) KR102257645B1 (fr)
CN (2) CN109364250A (fr)
AU (3) AU2013329421A1 (fr)
BR (1) BR112015007780A2 (fr)
CA (1) CA2887682A1 (fr)
EA (1) EA201590709A1 (fr)
HK (1) HK1213794A1 (fr)
IL (2) IL238117B (fr)
MX (2) MX2015004436A (fr)
WO (1) WO2014058875A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524731A (ja) * 2016-07-13 2019-09-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ−１アンタゴニストの投与計画及び脱髄障害の処置のための使用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010005570A2 (fr) 2008-07-09 2010-01-14 Biogen Idec Ma Inc. Compositions comprenant des anticorps anti-lingo ou leurs fragments
EA030716B1 (ru) 2012-05-14 2018-09-28 Байоджен Ма Инк. Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
US20170283804A1 (en) * 2014-09-19 2017-10-05 Ionis Pharmaceuticals, Inc. Antisense compounds and uses thereof
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
US10435467B2 (en) * 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
EP3302465A1 (fr) 2015-06-05 2018-04-11 Vertex Pharmaceuticals Incorporated Triazoles pour le traitement de maladies liées à la démyélinisation
WO2018106641A1 (fr) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles pour le traitement de maladies démyélinisantes
WO2018106646A1 (fr) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles pour traiter des maladies démyélinisantes
WO2018106643A1 (fr) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Azoles hétérocycliques pour le traitement de maladies de démyélinisation
EP3600553A4 (fr) 2017-03-26 2020-09-02 Mapi Pharma Ltd. Systèmes de dépôt de glatiramère pour le traitement de formes progressives de sclérose en plaques
EP3624838B1 (fr) * 2017-05-15 2023-01-25 Oncoimmune, Inc. Procédés d'utilisation de cd24 soluble pour la neuroprotection et la remyélinisation
US11412968B2 (en) 2017-09-12 2022-08-16 Get Together, Inc System and method for a digital therapeutic delivery of generalized clinician tips (GCT)
CN112153967A (zh) * 2018-04-13 2020-12-29 莫迪凯·舍维龙 治疗脱髓鞘的组合物和方法
CA3144567A1 (fr) 2019-06-21 2020-12-24 Scott Crowe Polypeptides
MX2021015763A (es) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Polipeptidos.
CN113584041A (zh) * 2021-04-15 2021-11-02 浙江警察学院 一种转基因斑马鱼(mbp:egfp)脱脊髓疾病模型的构建方法
KR20230171226A (ko) * 2022-06-13 2023-12-20 고려대학교 산학협력단 키나아제 저해제를 유효성분으로 포함하는 탈수초성 질환 예방 또는 치료용 약학적 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09506603A (ja) * 1993-12-16 1997-06-30 ドクトル レンチュレル アルツナイミッテル ゲーエムベーハー ウント コー 多発性硬化症治療でのペントキシフィリンの使用
JP2005522434A (ja) * 2002-02-06 2005-07-28 アレス トレーディング ソシエテ アノニム 脱髄性疾患における腫瘍壊死因子とインターフェロンの組み合わせ
JP2010515456A (ja) * 2007-01-09 2010-05-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｐ３５抗体およびその使用
JP2011225577A (ja) * 2003-01-24 2011-11-10 Elan Pharmaceuticals Inc 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
JP2532858B2 (ja) 1985-04-01 1996-09-11 セルテツク リミテツド 形質転換したミエロ―マ細胞系
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1892296A1 (fr) 1988-09-02 2008-02-27 Dyax Corporation Production et sélection de protéines de liaison diversifiées recombinantes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991000906A1 (fr) 1989-07-12 1991-01-24 Genetics Institute, Inc. Animaux chimeriques et transgeniques pouvant produire des anticorps humains
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
CA2405246A1 (fr) 1990-12-03 1992-06-11 Genentech, Inc. Methode d'enrichissement de proteines variantes aux proprietes liantes a lterees
ES2330052T3 (es) 1991-03-01 2009-12-03 Dyax Corporation Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas.
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
EP0519596B1 (fr) 1991-05-17 2005-02-23 Merck & Co. Inc. Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
WO1994004678A1 (fr) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulines exemptes de chaines legeres
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE669986T1 (de) 1992-11-13 1996-10-10 Idec Pharma Corp Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung.
DE69419721T2 (de) 1993-01-12 2000-04-27 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
DE69407758T3 (de) 1993-02-09 2007-05-24 Biogen Idec Ma Inc., Cambridge Antikörper zur behandlung von insulinabhängigem diabetes
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US20030143204A1 (en) 2001-07-27 2003-07-31 Lewis David L. Inhibition of RNA function by delivery of inhibitors to animal cells
CN1175111C (zh) 1997-03-14 2004-11-10 艾德药品公司 将基因整合至哺乳动物细胞特定位点的方法及所用载体
AU2001245793A1 (en) 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
EP1419179B1 (fr) 2001-08-10 2010-03-03 Aberdeen University Domaines de liaison d'antigenes issus de poissons
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
US20030166282A1 (en) 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
WO2003093430A2 (fr) 2002-05-03 2003-11-13 The Board Of Trustees Of The Leland Stanford Junior University Procedes et compositions a utiliser dans la preparation d'arnsi
US7700758B2 (en) 2002-08-12 2010-04-20 New England Biolabs, Inc. Methods and compositions relating to gene silencing
UA88604C2 (ru) * 2003-01-24 2009-11-10 Элан Фармасьютикалз, Инк. Применение антитела, которое связывается с альфа-4-интегрином, для лечения демиелинизирующего заболевания
PT2248899E (pt) 2003-03-19 2015-09-23 Biogen Ma Inc Proteína de ligação do receptor nogo
KR20040086884A (ko) 2003-03-22 2004-10-13 제일모직주식회사 난연성 열가소성 수지 조성물
ES2395094T3 (es) 2004-06-24 2013-02-08 Biogen Idec Ma Inc. Tratamiento de afecciones que implican la desmielinización
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
WO2010005570A2 (fr) * 2008-07-09 2010-01-14 Biogen Idec Ma Inc. Compositions comprenant des anticorps anti-lingo ou leurs fragments
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
ME02556B (fr) 2011-02-07 2017-02-20 Biogen Ma Inc Agents modulant s1p
GB201103526D0 (en) * 2011-03-02 2011-04-13 Summit Corp Plc Selective glycosidase inhibitors and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09506603A (ja) * 1993-12-16 1997-06-30 ドクトル レンチュレル アルツナイミッテル ゲーエムベーハー ウント コー 多発性硬化症治療でのペントキシフィリンの使用
JP2005522434A (ja) * 2002-02-06 2005-07-28 アレス トレーディング ソシエテ アノニム 脱髄性疾患における腫瘍壊死因子とインターフェロンの組み合わせ
JP2011225577A (ja) * 2003-01-24 2011-11-10 Elan Pharmaceuticals Inc 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
JP2010515456A (ja) * 2007-01-09 2010-05-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｐ３５抗体およびその使用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524731A (ja) * 2016-07-13 2019-09-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ−１アンタゴニストの投与計画及び脱髄障害の処置のための使用
JP7149257B2 (ja) 2016-07-13 2022-10-06 バイオジェン・エムエイ・インコーポレイテッド Ｌｉｎｇｏ－１アンタゴニストの投与計画及び脱髄障害の処置のための使用

Also Published As

Publication number Publication date
AU2013329421A1 (en) 2015-04-30
EP3750560A2 (fr) 2020-12-16
CA2887682A1 (fr) 2014-04-17
US20190038744A1 (en) 2019-02-07
MX2020006431A (es) 2020-09-17
KR20210063443A (ko) 2021-06-01
US20200276303A1 (en) 2020-09-03
AU2018203688A1 (en) 2018-06-14
US20150238602A1 (en) 2015-08-27
JP2018044014A (ja) 2018-03-22
US20210260185A1 (en) 2021-08-26
HK1213794A1 (zh) 2016-07-15
CN109364250A (zh) 2019-02-22
IL269852A (en) 2019-11-28
BR112015007780A2 (pt) 2017-11-28
CN104870014A (zh) 2015-08-26
AU2020203196A1 (en) 2020-06-04
EP2906240A2 (fr) 2015-08-19
IL238117B (en) 2019-10-31
EA201590709A1 (ru) 2015-09-30
KR102257645B1 (ko) 2021-06-01
JP2022023182A (ja) 2022-02-07
IL238117A0 (en) 2015-05-31
IL269852B (en) 2021-08-31
WO2014058875A2 (fr) 2014-04-17
KR20150064752A (ko) 2015-06-11
WO2014058875A3 (fr) 2014-06-12
JP2020055881A (ja) 2020-04-09
EP3750560A3 (fr) 2021-03-24
MX2015004436A (es) 2015-06-24

Similar Documents

Publication Publication Date Title
US20210260185A1 (en) Combination Therapies and Uses for Treatment of Demyelinating Disorders
US20210277111A1 (en) Lingo-1 antagonists and uses for treatment of demyelinating disorders
US20210403556A1 (en) Dosage Regimens of Lingo-1 Antagonists and Uses for Treatment of Demyelinating Disorders
US20200392229A1 (en) Methods of use of anti-sortilin antibodies
CN111789954B (zh) 延缓衰老的方法和药物
US20240132597A1 (en) Methods of use of anti-sortilin antibodies
JP2023530255A (ja) 末梢神経再生を促進するためのｃｘｃｌ１３結合分子の使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170626

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170913

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180308

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20180316